Hepatic Tumors

Hepatic Tumors

Overview

·      Cancerous (malignant) or benign

·      The liver is a common site for both primary tumor development and metastatic spread from other organs due to its extensive microvasculature and filtering function.

·      Accurate diagnosis and classification are essential for appropriate patient management and therapy selection.

Cancerous Tumors

Categories

  • Primary Tumors:

    • Originate from the cells within the liver parenchyma (e.g., hepatocytes) or bile ducts (e.g., cholangiocytes).

    • Relatively uncommon in the general population compared to metastatic liver disease, but specific types like Hepatocellular Carcinoma (HCC) are highly significant, especially in high-risk populations.

    • The liver's unique regenerative capacity can sometimes contribute to the development of these tumors under conditions of chronic injury and inflammation.

  • Metastatic Tumors:

    • Arise from cancerous cells that have traveled from a primary cancer site elsewhere in the body (e.g., colon, breast, lung, stomach, pancreas) and established secondary growth in the liver.

    • The liver's rich sinusoidal capillaries and its role as a filter for blood from the gastrointestinal tract (via the portal vein) make it a frequent target for metastatic spread.

Benign Tumors

  • Hepatic Adenomas:

    • More prevalent among women in their reproductive years, particularly those with a history of oral contraceptive use.

    • Incidence increased significantly with the advent of higher-dose oral contraceptives, though it has decreased with lower-dose formulations.

    • Adenomas can carry risks such as spontaneous hemorrhage (which can be life-threatening) and, rarely, malignant transformation into HCC.

    • Long-term follow-up and cessation of oral contraceptives are often recommended.

  • Focal Nodular Hyperplasia (FNH):

    • Common in women aged 20-30 years, it is a benign lesion characterized by a central stellate scar and is typically asymptomatic with no malignant potential.

  • Hemangioma:

    • The most prevalent benign tumor found in the liver, with up to 5% of adults harboring small forms of this vascular malformation. They are usually asymptomatic and discovered incidentally. Large hemangiomas can cause symptoms due to mass effect but rarely require intervention.

Types of Primary Cancerous Tumors

Common Types

  • Hepatocellular Carcinoma (HCC) (also referred to as Hepatoma):

    • This is the most common primary liver cancer, accounting for the majority of cases. It typically develops in the context of chronic liver disease and cirrhosis, particularly associated with chronic hepatitis B and C virus infections. HCC is an aggressive cancer with a guarded prognosis if not detected and treated early.

  • Cholangiocarcinoma:

    • Originates in the epithelial lining of the bile ducts, either intrahepatic (within the liver) or extrahepatic (outside the liver). These tumors are generally aggressive and challenging to treat, often presenting at an advanced stage.

  • Mixed Tumors:

    • These rare tumors contain both epithelial (e.g., hepatocellular or cholangiocellular) and mesenchymal (e.g., sarcomatous) components. An example is combined hepatocellular-cholangiocarcinoma.

  • Angiosarcoma:

    • A rare and highly aggressive tumor that originates in the endothelial cells lining the blood vessels of the liver. It has a poor prognosis and is sometimes associated with exposure to certain toxins like vinyl chloride, arsenic, or thorium dioxide.

  • Hepatoblastoma:

    • This is the most common malignant liver tumor in children, typically occurring in infants and young children. It can cause hormonal changes leading to early (precocious) puberty due to the tumor's production of human chorionic gonadotropin (hCG).

Risk Factors for Cancerous Hepatic Tumors

  • Viral Hepatitis:

    • Chronic infection with Hepatitis B (HBV) and Hepatitis C (HCV) viruses are the most significant global risk factors, leading to chronic inflammation, fibrosis, and ultimately cirrhosis, a precursor to HCC.

  • Alcohol:

    • Chronic alcohol abuse leads to alcoholic liver disease, which can progress to cirrhosis, significantly increasing the risk of HCC. The mechanism involves liver damage, inflammation, and cellular regeneration.

  • Cirrhosis:

    • Regardless of the underlying cause (viral hepatitis, alcohol, non-alcoholic steatohepatitis (NASH), hemochromatosis, primary biliary cholangitis), cirrhosis is the strongest risk factor for HCC. About 80% to 90% of HCC cases develop in cirrhotic livers.

  • Non-alcoholic Fatty Liver Disease (NAFLD) / Non-alcoholic Steatohepatitis (NASH):

    • Increasingly recognized as a significant risk factor, particularly in obese and diabetic individuals, progressing to cirrhosis and then HCC.

  • Exposure to Toxins:

    • Such as aflatoxins (naturally occurring toxins produced by certain fungi found on agricultural crops like corn and peanuts, especially in warm, humid regions) or industrial chemicals like vinyl chloride (used in PVC manufacturing).

  • Anabolic Steroids:

    • Prolonged intake of anabolic-androgenic steroids has been associated with an increased risk of liver adenomas and, rarely, HCC.

  • Age:

    • The incidence of liver cancer generally increases with age, with a higher incidence in individuals over 60 years, although it can occur earlier, particularly in conjunction with viral hepatitis or genetic predispositions.

  • Sex:

    • Men are at twice the risk compared to women for HCC, possibly due to hormonal factors, higher rates of alcohol consumption, and higher prevalence of chronic HBV/HCV in some populations.

  • Race:

    • Individuals of Asian descent have historically had the highest risk of HCC, largely due to endemic HBV infection in these regions.

  • Smoking:

    • Associated with increased liver cancer risk, especially when combined with other risk factors like alcohol or viral hepatitis.

  • Genetics:

    • Hereditary factors play a role, with certain genetic syndromes (e.g., hemochromatosis, alpha-1 antitrypsin deficiency) leading to cirrhosis and increased cancer risk.

Metastatic Tumors

Common Primary Sites for Metastasis to the Liver

Due to the liver's extensive blood supply and its role in filtering blood from the gastrointestinal tract, it is a common site for metastases from various primary cancers:

  • Colon: Colorectal cancer is the most common cause of liver metastases.

  • Carcinoid Tumors: Neuroendocrine tumors, often originating in the GI tract, frequently metastasize to the liver.

  • Breast: Breast cancer can spread to the liver.

  • Ovarian: Ovarian cancer, especially in advanced stages.

  • Lung: Both non-small cell and small cell lung cancer can metastasize to the liver.

  • Renal (Kidney): Clear cell renal cell carcinoma is prone to liver metastasis.

  • Prostate: Prostate cancer can spread to the liver, though less commonly than to bone.

  • Pancreas: Pancreatic adenocarcinoma frequently metastasizes to the liver.

  • Stomach: Gastric cancer often spreads to the liver.

Symptoms and Signs of Cancerous Hepatic Tumors

  • Initial Symptoms:

    • Many hepatic tumors, especially in early stages, may be asymptomatic or cause only vague, non-specific symptoms, leading to late diagnosis.

  • Pain:

    • A common symptom as the tumor grows and stretches the liver capsule or invades adjacent structures.

    • This can manifest as a dull ache in the right upper abdomen, referred pain to the right shoulder or back (due to diaphragmatic irritation), or epigastric discomfort.

  • Fever:

    • Can occur in liver cancer even without an infection, often due to tumor necrosis (death of tumor cells) or the body's inflammatory response to the tumor.

  • Jaundice:

    • Yellowing of the skin and eyes, typically only occurs if there is significant bile duct obstruction (e.g., by a tumor near the porta hepatis or cholangiocarcinoma) or extensive invasion/destruction of liver tissue impairing bilirubin metabolism.

  • Indigestion:

    • Non-specific symptom, potentially due to mass effect compressing the stomach.

  • Loss of Appetite:

    • Common in advanced cancer (anorexia), leading to significant weight loss and cachexia.

  • Nausea:

    • May accompany loss of appetite or indigestion.

  • Swelling:

    • Either abdominal swelling (ascites, due to fluid accumulation in the peritoneal cavity, often from portal hypertension or peritoneal tumor spread) or leg swelling (edema, due to systemic effects like hypalbuminemia or venous compression).

  • Generalized Weakness:

    • Often seen in advanced cases, contributing to fatigue and reduced physical activity.

  • Hepatomegaly:

    • An enlarged liver, which may be palpable during physical examination, indicating significant tumor burden or inflammation.

  • Splenomegaly:

    • Enlarged spleen, often secondary to portal hypertension caused by advanced liver disease or tumor involvement of the portal vein.

Biopsy Review

  • Patient Management Post-Biopsy:

    • Positioning:

      • The patient should lie on the affected side (the side where the biopsy was performed) after the procedure for several hours.

      • This applies direct pressure to the biopsy site, helping to tamponade any bleeding and minimize bleeding risks.

    • Vital Signs (VS) Monitoring:

      • Frequent monitoring for pulse increase (tachycardia), blood pressure (BP) drop (hypotension), and respiratory rate (RR) increase (tachypnea) is crucial.

      • Can be early indicators of internal bleeding, hemorrhage, or hypovolemic shock.

      • Monitoring should be done every 15 minutes for the first hour, then every 30 minutes for the next two hours, and then hourly.

    • Bleeding and Bruising:

      • Watch for signs of active external bleeding (oozing, frank hemorrhage) or bruising (ecchymosis) at the needle insertion site.

    • Pain Management:

      • Post-procedure pain is common.

      • Administer prescribed analgesics and assess pain levels regularly.

      • Increasing or severe pain, especially sharp, unremitting abdominal pain, can indicate complications like hemorrhage or peritonitis.

Staging of Liver Cancer

Localized Resectable Tumor

  • Tumor is confined to a portion of the liver and can be completely surgically removed with curative intent.

    • Resectability depends on tumor size, location (e.g., proximity to major vessels), number of tumors, and the remaining liver function (especially in cirrhotic patients).

  • Detection of liver cancer may involve several findings, although they can have other explanations:

    • Fever of unknown origin: Can sometimes be the initial presenting symptom.

    • Hepatomegaly and splenomegaly: Palpable enlargement of the liver and spleen (often due to portal hypertension).

    • Enlarged and hardened lymph nodes: May indicate regional spread of the cancer.

Diagnostic Tests for Liver Cancer

  • Abdominal Ultrasound:

    • Often the first imaging modality used due to its non-invasiveness and cost-effectiveness.

    • Used to differentiate solid masses from benign fluid accumulations (cysts), assess liver architecture, and guide biopsy procedures.

  • Blood Tests:

    • May show either normal or abnormal counts for Red Blood Cells (RBCs) and Liver Function Tests (LFTs).

    • LFTs:

      • Elevated aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and bilirubin can indicate liver damage, inflammation, or biliary obstruction.

    • Clotting tests:

      • Prothrombin time (PT) and Partial Thromboplastin Time (PTT) can be abnormal (prolonged) due to impaired synthesis of clotting factors by the diseased liver, indicating liver dysfunction.

    • Alpha-fetoprotein (AFP):

      • A key tumor marker, often significantly elevated in HCC patients, particularly in advanced stages.

      • Used for screening in high-risk patients (e.g., those with cirrhosis), diagnosis, and monitoring treatment response and recurrence.

Treatment Options for Liver Cancer

Surgical Options

  • Surgery (resection or transplantation) is only available to a small percentage of candidates due to various factors, including the extent of the disease, overall patient health, and the adequacy of remaining liver function (especially critical in patients with underlying cirrhosis).

  • Chemotherapy:

    • Systemic chemotherapy for advanced HCC has historically shown limited effectiveness compared to other cancers.

    • However, newer targeted therapies (e.g., sorafenib, lenvatinib) and immunotherapies (e.g., atezolizumab/bevacizumab combination) have significantly improved outcomes for advanced HCC.

    • Adriamycin (doxorubicin) and 5-Fluorouracil (5-FU) were older standard agents, though their role has diminished for systemic use in HCC.

  • Radiation Therapy:

    • Typically applied post-surgery for metastases or for local control in palliative scenarios.

    • No proven benefits for primary curative intent for HCC, but can be effective for symptom palliation (e.g., pain from bone metastases).

Staging Continued: Localized Unresectable Tumors

  • Some localized tumors may be deemed unresectable despite being confined to the liver.

  • Can be due to factors such as involvement of vital blood vessels (e.g., portal vein, hepatic veins), extensive multi-nodular disease, unfavorable tumor location, or severe underlying liver impairment (decompensated cirrhosis).

  • Symptoms in such cases may include:

    • Abdominal swelling (ascites): Indicating advanced liver dysfunction or portal hypertension.

    • Jaundice: Due to significant liver damage or biliary obstruction.

    • Leg swelling (edema): Often associated with hypoalbuminemia or fluid retention.

  • CT and MRI scans:

    • These advanced imaging modalities are instrumental in assessing tumor extent, vascular involvement, potential lymph node metastases, and involvement of adjacent abdominal structures with high precision.

Technological Assistance in Treatment

  • Arteriography:

    • Involves the injection of a dye into arteries supplying the liver, followed by X-ray analysis, to visualize the blood supply to the tumor (tumor vascularity) and identify feeder vessels.

  • No standardized therapy:

    • For unresectable HCC, there isn't a single standardized curative therapy.

    • Multidisciplinary tumor boards are crucial for personalized treatment plans.

    • Participation in clinical trials is often encouraged to test new treatments.

  • Liver Transplantation:

    • May benefit a select group of patients with few small tumors (typically < 3 tumors that are < 5 cm in size, or one tumor < 7 cm, without vascular invasion or extrahepatic spread – known as the Milan or UCSF criteria) and often without active hepatitis B or other contraindications.

    • Offers the benefit of removing both the tumor and the underlying cirrhotic liver.

  • Cryosurgery and Radiofrequency Ablation (RFA):

    • Newer local ablative techniques aimed at facilitating destruction of otherwise unresectable tumors by freezing (cryosurgery) or heating (RFA, Microwave Ablation - MWA) the tumor cells.

    • Typically used for smaller tumors.

Advanced Disease Management

Stage Characteristics

  • Advanced disease:

    • Characterized by tumors that have spread extensively across multiple or all liver lobes and/or metastasized to distant organs such as the lungs, lymph nodes, and bones.

    • This stage often indicates a poorer prognosis and focuses on palliative and systemic therapies.

    • Treatment approaches as earlier plus:

      • Biopsy Techniques:

        • Either Fine Needle Aspiration (FNA) or regular core needle biopsy to accurately differentiate between primary liver cancer and metastasis from other organs, which significantly impacts treatment decisions.

      • Standard Therapy:

        • For advanced HCC, there is a lack of a single curative standard treatment.

        • Current standard systemic therapies, which have improved survival, include targeted therapies (e.g., multi-kinase inhibitors like sorafenib, Lenvatinib) and immunotherapies (e.g., PD-1 inhibitors like nivolumab, pembrolizumab, or combinations like atezolizumab + bevacizumab). Single-agent chemotherapy with Adriamycin or 5-Fluorouracil is less commonly used as first-line systemic treatment today; hybrid treatments typically involve combinations of newer agents.

      • Radiation:

        • Along with chemotherapy may relieve the pain of large liver masses

        • Radiation to painful bone or other metastases may also be appropriate.

      • Chemoembolization:

        • Administering a combination of chemotherapy and colloid particles directly into the liver tumor via its main (hepatic artery) may improve symptoms even when there is metastatic disease.

      • Investigational methods:

        • Combination chemo or new drugs including derivatives or Adriamycin and 5-FU may prove beneficial.

Staging Systems for Liver Cancer

AJCC - TNM System

  • The American Joint Committee on Cancer (AJCC) TNM staging system is a widely used and crucial tool for classifying liver cancer. It provides a standardized method to describe the anatomical extent of the disease, guiding prognosis and treatment planning.

  • T (Tumor): Describes the size and number of the primary tumors and their local invasiveness, including whether they have invaded blood vessels.

  • N (Nodes): Assesses whether the cancer has spread to nearby regional lymph nodes.

  • M (Metastasis): Evaluates if the cancer has metastasized to distant organs, with common sites being the lungs and bones.

TNM Factors

  • Numbers and Letters: Accompany T, N, and M classifications, indicating the severity and extent of the disease. The numbers typically denote increasing severity, generally from 0 to 4 for T-stages, and 0 or 1 for N and M stages.

Staging Breakdown

1.   T Stages: Describe the primary tumor characteristics:

o   T0: No evidence of primary tumor.

o   T1: Single tumor of any size, without vascular invasion.

o   T2: Single tumor of any size with vascular invasion, OR multiple tumors none larger than 5 cm.

o   T3: Multiple tumors larger than 5 cm, OR a tumor (or tumors) invading a major branch of the portal vein or hepatic vein.

o   T4: Tumor infiltrating neighboring organs (excluding the gallbladder) or perforating the visceral peritoneum.

2.   N Stages: Describe regional lymph node involvement:

o   N0: No metastasis to regional lymph nodes.

o   N1: Metastasis to regional lymph nodes present.

3.   M Stages: Describe distant metastasis:

o   MX: Distant spread cannot be evaluated (information unavailable).

o   M0: No distant metastasis (cancer confined to regional area).

o   M1: Distant metastasis confirmed (cancer has spread to other parts of the body).

Benign (Non-cancerous) Tumors of the Liver

Different Types

  • Hepatic Adenoma: Most often seen in women of childbearing age.

  • Focal Nodular Hyperplasia: Common in women aged 20-30 years.

  • Hemangioma: The most prevalent benign tumor found in the liver, with up to 5% of adults holding small forms of this tumor.

Nonsurgical Treatments for Liver Cancer

  • Underlying Cirrhosis Consideration:

    • The presence and severity of underlying cirrhosis is a prominent risk factor for the development of liver cancer and significantly influences the choice and outcomes of both surgical and non-surgical treatments.

    • It complicates treatment decisions and increases the risk of complications.

  • Palliative Measures:

    • Non-surgical treatments primarily focus on palliation (symptom control and quality of life) for advanced or unresectable tumors, or as bridge-to-transplant therapies.

      • Radiation Therapy: While limited for curative intent due to the liver's radiation sensitivity, it can be used for local control of tumors, to relieve pain, or for specific metastases (e.g., bone metastases).

      • Chemotherapy: Systemic chemotherapy has had historically limited success.

      • Locoregional therapies, such as Transarterial Chemoembolization (TACE) and Transarterial Radioembolization (TARE), are highly effective.

      • TACE involves delivering chemotherapy agents directly to the tumor via the hepatic artery, followed by embolization of the blood supply.

      • Using an implantable pump for direct hepatic arterial infusion can yield better tumor responses for specific agents and fewer systemic side effects compared to traditional intravenous methods.

      • Thermal Ablation: Techniques like Radiofrequency Ablation (RFA) and Microwave Ablation (MWA) are designed to induce coagulation necrosis (destroy tissue with heat) in smaller tumors (typically < 3-5 cm).

      • They are minimally invasive, often performed percutaneously, and offer local control for suitable lesions.

Surgical Treatments for Liver Cancer

  • Choice for Hepatocellular Carcinoma (HCC):

    • Surgical resection (removal of part of the liver) is the treatment of choice for HCC when it is confined to one lobe, and the patient has good liver function.

    • Careful assessment of liver function (e.g., absence of portal hypertension, low bilirubin, adequate future liver remnant) is critical.

  • Lobectomy/Segmentectomy:

    • Involves the surgical removal of a lobe or segment of the liver containing the tumor to prevent metastasis.

    • The liver has a remarkable capacity for regeneration, allowing for significant portions to be removed.

  • Cryosurgery:

    • Local ablation with ethanol or microwave coag.

  • Liver Transplantation:

    • Offers the best long-term outcomes for selected patients with early-stage HCC, as it removes both the tumor and the underlying diseased, cirrhotic liver.

    • However, it requires a suitable donor organ, and patients must undergo long-term immunosuppressant therapy to prevent rejection, with a risk of recurrence even post-transplant.

Postoperative Considerations

Surgical Monitoring

  • Hypoglycemia:

    • Maintaining stable blood sugar levels is crucial in the post-operative period.

    • The resected liver may have reduced gluconeogenic capacity, leading to hypoglycemia, especially in patients with underlying liver disease.

  • Hypovolemia:

    • Monitoring and managing blood loss is paramount.

    • Extensive liver surgery can involve significant blood loss, requiring vigilant monitoring of vital signs, hemoglobin, and hematocrit levels.

    • This often necessitates blood transfusions and/or intravenous fluid therapy to maintain hemodynamic stability.

  • Hypothermia:

    • Monitoring body temperature is important post-surgery.

    • Patients can become hypothermic during prolonged operations, which can lead to complications such as coagulopathy and cardiac arrhythmias.

  • Infection Prevention:

    • Vigilance for signs of post-surgical infections (e.g., fever, wound erythema, elevated white blood cell count) is critical, as liver surgery patients can be immunocompromised due to underlying liver disease or the stress of surgery.

Patient Education & Support

  • What Patients Should Expect Post-Procedure:

    • Dietary adjustments:

      • Patients often require a modified diet initially, with slow reintroduction of foods as bowel function returns and liver function stabilizes.

      • Nutritional support is vital for recovery.

    • Potential need for drainage systems:

      • Drains may be placed during surgery to remove fluid or blood from the surgical site, preventing collections and complications.

      • Patients need education on drain care and monitoring.

      • Monitor incisions for signs of infection.

    • Discussions surrounding chemotherapy and radiation therapy:

      • Thorough counseling on potential adjuvant therapies, their benefits, side effects, and administration schedules.

    • Psychological support and community help:

      • Providing access to support groups, counseling services, and social workers to help patients and their families cope with the emotional and practical challenges of cancer and recovery.

    • Monitoring for infections and ensuring follow-up appointments:

      • Patients must be educated on signs of infection to report immediately and given a clear schedule for follow-up appointments (e.g., imaging, blood tests, clinical evaluations) to monitor recovery and detect recurrence.

    • Educating patients about port management:

      • If a chemotherapy port is inserted, patients need detailed instructions on its care, signs of infection, and proper usage.

    • Reassuring them through the recovery process during follow-ups is critical for adherence and overall well-being.